Wednesday, July 8, 2026

Drug profile · INN

treprostinil

treprostinil (TREPROSTINIL SCIPHARM SÀRL) is a prostanoid ip receptor agonist. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved EMA: approved Blood and blood forming organs (B01) B01AC21
US status approved
Patents linked 20
Pipeline programs 43
News articles 0
Drug details — treprostinil
US status
approved
Class
Blood and blood forming organs (B01)
Route
INHALATION
Patents
20
Programs
43
Data quality
0.89

Quick answer

treprostinil (TREPROSTINIL SCIPHARM SÀRL) is a prostanoid ip receptor agonist. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN treprostinil
Brand TREPROSTINIL SCIPHARM SÀRL
Mechanism Prostanoid IP receptor agonist
Target Prostacyclin receptor
Therapeutic class Blood and blood forming organs (B01)
Route INHALATION
Formulation INJECTABLE
ATC code B01AC21

Mechanism of action

Prostanoid IP receptor agonist

Primary target: Prostacyclin receptor

Approval history

Authority Status Date
FDA approved
EMA approved

Pipeline programs

  1. INS1009-203 Phase 3 · Insmed Incorporated · Pulmonary Arterial Hypertension
  2. INS1009-212 Phase 3 · Insmed Incorporated · Pulmonary Hypertension Associated with Interstitial Lung Dis
  3. INS1009-311 Phase 3 · Insmed Incorporated · Pulmonary Hypertension Associated with Interstitial Lung Dis
  4. Inhaled Treprostinil Phase 3 · United Therapeutics Europe · Idiopathic Pulmonary Fibrosis
  5. Inhaled treprostinil Phase 3 · United Therapeutics Europe · Pulmonary Hypertension
  6. Inhaled treprostinil solution Phase 3 · United Therapeutics Europe · Pulmonary Hypertension
  7. Oral Treprostinil Phase 3 · United Therapeutics Europe · Pulmonary Arterial Hypertension
  8. Oral Treprostinil Phase 3 · United Therapeutics Europe · Pulmonary Hypertension Associated With Sickle Cell Disease

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)
  1. US 12357599

    Prodrugs of treprostinil

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12173021

    Treprostinil prodrugs

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12168071

    Treprostinil derivatives and their use in pharmaceutical compositions

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11826327

    Treatment for interstitial lung disease

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11826328

    Stable treprostinil prodrugs

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11723887

    Process to prepare treprostinil, the active ingredient in Remodulin®

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11672775

    Treprostinil prodrugs

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11634443

    Treprostinil prodrugs

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11571444

    Enhancement of MSC immunomodulatory properties by treprostinil

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11357782

    Treprostinil administration by inhalation

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11236035

    Salts of treprostinil

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10716793

    Treprostinil administration by inhalation

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10695308

    Inhalation formulations of treprostinil

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10548863

    Process to prepare treprostinil, the active ingredient in Remodulin®

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10478410

    Process to prepare treprostinil, the active ingredient in Remodulin®

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10376525

    Treprostinil administration by inhalation

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10322099

    Process to prepare treprostinil, the active ingredient in remodulin®

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10167247

    Solid forms of treprostinil

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10076505

    Inhalation formulations of Treprostinil

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 9988334

    Salts of treprostinil

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is treprostinil?

treprostinil (TREPROSTINIL SCIPHARM SÀRL) is a prostanoid ip receptor agonist. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for treprostinil?

TREPROSTINIL SCIPHARM SÀRL is a marketed brand name for treprostinil. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of treprostinil?

treprostinil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.